Recombinant T-cell receptor ligand (RTL) for treatment of multiple sclerosis: A double-blind, placebo-controlled, phase 1, dose-escalation study
- Vijayshree Yadav
- , Dennis N. Bourdette
- , James D. Bowen
- , Sharon G. Lynch
- , David Mattson
- , Jana Preiningerova
- , Christopher T. Bever
- , Jack Simon
- , Andrew Goldstein
- , Gregory G. Burrows
- , Halina Offner
- , Al J. Ferro
- , Arthur A. Vandenbark
Research output: Contribution to journal › Article › peer-review
39
Scopus
citations